Cheryl Mc Alpine
About Cheryl Mc Alpine
Cheryl McAlpine is the Director of Translational Sciences at Adaptimmune, where she has worked since 2020. With over 18 years of experience in the pharmaceutical and biotech sectors, she has held various leadership roles and possesses expertise in drug development across multiple therapeutic areas.
Current Role at Adaptimmune
Cheryl McAlpine serves as the Director of Translational Sciences at Adaptimmune, a position she has held since 2020. In this role, she is responsible for overseeing the translational aspects of drug development, ensuring that scientific research effectively translates into viable therapeutic options. Her work is based in Abingdon, England, United Kingdom, where she utilizes her extensive background in drug development to guide projects from discovery through clinical phases.
Previous Experience in Pharmaceutical Development
Cheryl McAlpine has over 18 years of experience in the pharmaceutical, biotech, and CRO sectors. Prior to her current role, she held several positions that contributed to her expertise in drug development. She worked as a Biomarker Group Leader at Immunocore from 2014 to 2020, and as a Development & Validation Team Leader at Merck Millipore from 2012 to 2014. Additionally, she served as a Senior Scientist and Team Leader at Merck from 2009 to 2010, and at Schering-Plough Research Institute from 2007 to 2009.
Educational Background
Cheryl McAlpine earned her PhD in Cardiovascular Physiology/Pharmacology from The University of Glasgow, where she studied from 1994 to 1997. Prior to her doctoral studies, she completed her BSc(Hons) in Physiology at the same institution from 1990 to 1994. This educational foundation has equipped her with a strong understanding of physiological processes, which she applies in her work in drug development.
Leadership and Project Management Skills
Cheryl McAlpine demonstrates effective leadership and project management skills, with a proven track record of building and motivating teams. Her ability to analyze and interpret complex data contributes to her meticulous attention to detail in her work. This skill set has been essential in her various roles throughout her career, particularly in managing drug development projects across different therapeutic areas.
Experience in Drug Development
Cheryl McAlpine possesses extensive experience in drug development, spanning from discovery through pre-clinical stages to IND and clinical PhI/II phases. Her expertise includes working with both New Chemical Entities (NCEs) and New Biological Entities (NBEs). This comprehensive background has enabled her to contribute significantly to the advancement of therapeutic options in the pharmaceutical industry.